sellWeak cluster of 2
Christina Rossi sold $150k of BPMC
CHIEF OPERATING OFFICER at Blueprint Medicines Corp. 1,172 shares at an average of $128.25, traded Jul 3, 2025, filed Jul 8, 2025.
Warning score
39Value
$150k
1,172 shares
Holdings after
63,546
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RoleCOO
- +11Trade size$150k at market
- 0Share of holdings soldSold 1.8% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-019507, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 3, 2025 | SOpen-market sale Common Stock | -1,172 | $128.25 | $150k | 63,546 | Jul 8, 2025 |
Related signals
Other insiders at Blueprint Medicines Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | Blueprint Medicines Corp | Percy H. Carter CHIEF SCIENTIFIC OFFICER | $135k 1,051 shares | -2% | |
| 38Weak | Blueprint Medicines Corp | Percy H. Carter CHIEF SCIENTIFIC OFFICER | $340k 2,659 shares | -5% | |
| 13Weak | Blueprint Medicines Corp | Jeffrey W. Albers director | $506k 5,000 shares | -3% | |
| 28Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $229k 2,274 shares | -3% | |
| 7Weak | Blueprint Medicines Corp | Ariel Hurley PRINCIPAL ACCOUNTING OFFICER | $284k 2,752 shares | -14% | |
| 21Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $231k 2,274 shares | -3% | |
| 25Weak | Blueprint Medicines Corp | Kate Haviland CHIEF EXECUTIVE OFFICER | $216k 2,498 shares | -1% | |
| 27Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $216k 2,274 shares | -3% | |
| 48Moderate | Blueprint Medicines Corp | Jeffrey W. Albers director | $512k 5,766 shares | -4% | |
| 15Weak | Blueprint Medicines Corp | Jeffrey W. Albers director | $659k 7,500 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.